{"doi":"10.1002/jvc2.219","title":"Predicting discontinuation of biologic therapy caused by adverse events in psoriasis patients—A Danish nationwide cohort study","abstract":"<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Some patients treated with biologic therapy for psoriasis experience adverse events causing treatment discontinuation.</jats:p></jats:sec><jats:sec><jats:title>Objectives</jats:title><jats:p>To identify predictors of adverse events resulting in discontinuation of biologics for psoriasis.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>This cohort study involved data from the Danish nationwide registry DERMBIO. A classification algorithm based on gradient‐boosted decision trees combined with a mixed‐effects model was applied to data on various drugs to predict treatment discontinuation caused by adverse events and to identify important predictors.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>This study comprised 4876 treatment series, including 3078 (63.1%) that were discontinued. With adverse events causing 19.6% of these, it was the second most frequent reason for discontinuation following ineffectiveness. The proportion of treatments discontinued due to adverse events was 20.0% [16.7%, 23.9%; 95% confidence interval (CI)] among patients that had discontinued their previous treatment series due to adverse events, and 11.6% [10.3%, 13.1%; 95% CI] among treatment series where the previous treatment was discontinued due to other reasons (<jats:italic>p</jats:italic> &lt; 0.001).</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>The proportion of treatment series discontinued due to adverse events among patients who had discontinued their previous treatment due to adverse events was 72.4% larger compared to those who discontinued their previous treatment for other reasons.</jats:p></jats:sec>","journal":"JEADV Clinical Practice","year":2023,"id":28823,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":160466,"name":"Troels C. Petersen","orcid":null,"position":1,"is_corresponding":false},{"id":160467,"name":"Julia‐Tatjana Maul","orcid":"0000-0002-9914-1545","position":2,"is_corresponding":false},{"id":160468,"name":"Jashin J. Wu","orcid":null,"position":3,"is_corresponding":false},{"id":160469,"name":"Trine Bertelsen","orcid":null,"position":4,"is_corresponding":false},{"id":160470,"name":"Lone Skov","orcid":"0000-0002-4784-9680","position":5,"is_corresponding":false},{"id":160471,"name":"Simon F. Thomsen","orcid":null,"position":6,"is_corresponding":false},{"id":160472,"name":"Jacob P. Thyssen","orcid":"0000-0003-3770-1743","position":7,"is_corresponding":false},{"id":160473,"name":"Alexander Egeberg","orcid":"0000-0001-8257-1816","position":8,"is_corresponding":false},{"id":160465,"name":"Mia‐Louise Nielsen","orcid":"0000-0002-1562-8568","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"24523987","pmcid":null,"openalex_id":"https://openalex.org/W4386640344","authors":[],"funders":[],"total_grants":0,"fwci":0.0,"citation_percentile":0.35985595,"influential_citations":0,"citation_trend":[],"oa_status":"gold","license":"cc-by","oa_locations":[{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jvc2.219","host_type":"journal"},{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jvc2.219","host_type":"GOLD"},{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jvc2.219","host_type":"publisher"},{"url":"https://onlinelibrary.wiley.com/doi/pdf/10.1002/jvc2.219","host_type":"publisher"},{"url":"https://doi.org/10.1002/jvc2.219","host_type":"journal"},{"url":"https://pure.au.dk/portal/en/publications/b029ebd4-b5cb-4963-8301-a5a2e9a188bf","host_type":""},{"url":"https://doaj.org/article/6cec022e83ed4456a16df050d8c8cca3","host_type":"repository"}],"fields_of_study":["Psoriasis: Treatment and Pathogenesis","Health Systems, Economic Evaluations, Quality of Life","Biosimilars and Bioanalytical Methods","Medicine"],"mesh_terms":[],"keywords":["Discontinuation","Adverse effect","Medicine","Psoriasis","Internal medicine","Cohort study","Cohort","Confidence interval","Danish","Dermatology"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-06-08T22:12:32.972306Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}